Insider Selling: Seattle Genetics, Inc. (SGEN) Insider Sells 20,148 Shares of Stock

Share on StockTwits

Seattle Genetics, Inc. (NASDAQ:SGEN) insider Clay B. Siegall sold 20,148 shares of the company’s stock in a transaction that occurred on Friday, February 8th. The stock was sold at an average price of $65.17, for a total value of $1,313,045.16. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Clay B. Siegall also recently made the following trade(s):

  • On Tuesday, January 8th, Clay B. Siegall sold 20,148 shares of Seattle Genetics stock. The stock was sold at an average price of $65.73, for a total value of $1,324,328.04.
  • On Monday, December 10th, Clay B. Siegall sold 20,148 shares of Seattle Genetics stock. The stock was sold at an average price of $59.74, for a total value of $1,203,641.52.

NASDAQ SGEN opened at $68.31 on Thursday. The company has a market capitalization of $10.44 billion, a PE ratio of -41.40 and a beta of 2.39. Seattle Genetics, Inc. has a 12 month low of $47.75 and a 12 month high of $84.37.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings data on Thursday, February 7th. The biotechnology company reported ($0.75) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.36). The company had revenue of $174.50 million during the quarter, compared to analyst estimates of $164.03 million. Seattle Genetics had a negative net margin of 34.01% and a negative return on equity of 19.33%. The company’s quarterly revenue was up 34.6% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.41) EPS. Analysts forecast that Seattle Genetics, Inc. will post -0.44 earnings per share for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of SGEN. Capital International Investors raised its stake in Seattle Genetics by 53.6% in the 3rd quarter. Capital International Investors now owns 9,414,375 shares of the biotechnology company’s stock valued at $726,037,000 after acquiring an additional 3,285,237 shares during the period. Frontier Capital Management Co. LLC raised its stake in Seattle Genetics by 943.8% in the 4th quarter. Frontier Capital Management Co. LLC now owns 1,166,968 shares of the biotechnology company’s stock valued at $66,120,000 after acquiring an additional 1,055,173 shares during the period. First Trust Advisors LP raised its stake in Seattle Genetics by 70.7% in the 3rd quarter. First Trust Advisors LP now owns 1,779,195 shares of the biotechnology company’s stock valued at $137,212,000 after acquiring an additional 736,621 shares during the period. Morgan Stanley raised its stake in Seattle Genetics by 107.5% in the 3rd quarter. Morgan Stanley now owns 296,026 shares of the biotechnology company’s stock valued at $22,830,000 after acquiring an additional 153,370 shares during the period. Finally, Vanguard Group Inc raised its stake in Seattle Genetics by 1.7% in the 3rd quarter. Vanguard Group Inc now owns 8,914,184 shares of the biotechnology company’s stock valued at $687,461,000 after acquiring an additional 148,979 shares during the period.

A number of equities analysts have weighed in on SGEN shares. reaffirmed a “hold” rating on shares of Seattle Genetics in a research report on Monday, October 22nd. Needham & Company LLC cut their price objective on Seattle Genetics to $73.00 and set a “buy” rating for the company in a report on Friday, October 26th. Barclays cut their price objective on Seattle Genetics from $95.00 to $90.00 and set an “overweight” rating for the company in a report on Friday, October 26th. Piper Jaffray Companies cut their price objective on Seattle Genetics to $66.00 and set a “neutral” rating for the company in a report on Thursday, October 25th. Finally, HC Wainwright reissued a “buy” rating and issued a $98.00 price objective on shares of Seattle Genetics in a report on Friday, October 26th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. The stock currently has an average rating of “Buy” and an average target price of $80.82.

WARNING: This piece was first reported by BBNS and is owned by of BBNS. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://baseballnewssource.com/2019/02/14/insider-selling-seattle-genetics-inc-sgen-insider-sells-20148-shares-of-stock/3214916.html.

Seattle Genetics Company Profile

Seattle Genetics, Inc, a biotechnology company, focuses on the development and commercialization of targeted therapies for the treatment of cancer worldwide. It markets ADCETRIS, an antibody-drug conjugate for the treatment of relapsed Hodgkin lymphoma and relapsed systemic anaplastic large cell lymphoma.

Recommended Story: LIBOR

Insider Buying and Selling by Quarter for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


Leave a Reply

 
© 2006-2019 BBNS.